Asthma Pipeline Pressure For AstraZeneca As STRATOS 1 Fails
Executive Summary
The failure of AstraZeneca's novel asthma therapy in its first pivotal trial is of little surprise but increases the pressure on its other late-stage asthma product in this key therapy area for the company.
You may also be interested in...
AstraZeneca Taps Pieris For Inhaled Asthma Anticalins
AstraZeneca is to pay $57.5m to get its hands on biotech Pieris Pharmaceuticals' Anticalin technology to bolster its early stage respiratory portfolio, with a lead product candidate already being prepared for Phase I.
AstraZeneca Hands LEO Dermatology Potential
AstraZeneca PLC is handing over two pipeline skin disease medicines, tralokinumab and brodalumab, to LEO Pharma for an upfront payment of $115m while it focuses on other key therapy areas. The UK big pharma has also put an end to its license with Valeant Pharmaceuticals for brodalumab in Europe in favor of its new partner.
What Future For Genentech's Lebrikizumab On Phase III Failure?
Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.